|Bid||218.78 x 1200|
|Ask||260.00 x 800|
|Day's range||213.82 - 219.32|
|52-week range||203.37 - 460.21|
|Beta (5Y monthly)||1.27|
|PE ratio (TTM)||26.67|
|Earnings date||02 Aug 2022 - 08 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||327.64|
Charles River's (CRL) industry knowledge in plasmid DNA production will benefit Ziphius Vaccines' early-stage saRNA manufacturing program.
It is hard to get excited after looking at Charles River Laboratories International's (NYSE:CRL) recent performance...
WILMINGTON, Mass. & MACCLESFIELD, England, June 28, 2022--Charles River announces the opening of their High Quality Plasmid DNA Centre of Excellence at Bruntwood SciTech’s Alderley Park.